Publications (Full List)

  1. Effect of Rosuvastatin on Progression of Carotid Intima Media Thickness in Low-Risk Individuals: Results of the METEOR Study. John R. Crouse III, MD; Joel S. Raichlen; Ward A. Riley; Gregory W. Evans; Mike K. Palmer; Daniel H. O'Leary; Diederick E. Grobbee; Michiel L. Bots, on behalf of the METEOR Study Group Accepted for publication JAMA 2007.
  2. Efficacy and Safety of rosuvastatin 40 mg vs atorvastatin 80 mg in high-risk patients with hypercholesterolemia: Results of the POLARIS study. Lawrence A Leiter, Robert S Rosenson, Evan Stein, John PD Reckless, Karl-Ludwig Schulte, Margo Schleman, Paul Miller, Michael Palmer and Froukje Sosef. Atherosclerosis (2007) article in press.
  3. Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study. Crouse JR III, Grobbee DE, O'Leary DH, Bots ML, Evans GW, Palmer MK, Riley WA, Raichlen JS; METEOR Study Group. Current Medical Research and Opinion 2007; 23: 641-648.
  4. Comparison of the Efficacy and Safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia- Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Michael B Clearfield, John Amerena, Jean-Pierre Bassand, Hugo R Hernandez-Garcia, Sam S Miller, Froukje FM Sosef, Michael K Palmer, and Brian S Bryzinski. Trials, 7: 35, 2006.
  5. Measuring Effects on Intima Media Thickness: an Evaluation of Rosuvastatin in Subclinical Atherosclerosis - The Rationale and Methodology of the METEOR study. JR Crouse, DE Grobbee, DH O’Leary, JJP Kastelein, ML Bots, GW Evans, MK Palmer, WA Riley, JS Raichlen. Cardiovascular Drugs and Therapy 18: 233-240, 2004.
  6. Rosuvastatin enhances lipid fluidity in atherogenic apoB-containing lipoproteins. R Prassl, M Caslake, C J Packard, M Palmer, J M Chapman, P N Durrington and P Laggner. Atherosclerosis Supplements, 3 (2), 187, abs 562, (2002).
  7. Goserelin versus CMF as Adjuvant Therapy in Premenopausal patient with Node-Positive Breast Cancer:  the ZEBRA Study. W Jonat, M Kaufmann, W Sauerbrei, R Blamey, J Cuzick, M Namer, I Fogelman, JC de Haes, A de Matteis, A Stewart, W Eiermann, I Szakolczai, M Palmer, M Schumacher, M Geberth, B Lisboa, on behalf of ZEBRA Trialists Group. Journal of Clinical Oncology, 2002; 20 (24): 4628-4635
  8. Clinical Determinants of survival in patient with S. Fluorouracil-based treatment for metastatic colorectal cancer: result of a multivariate analysis of 3825 patients. C-H Kohn, D Cunningham, F Di Costanzo, B Glimelius, G Blizham, A Aranda, W Scheithamer, P Rougier, M Palmer, J Wils, B Baron, F Pignatti, P Schoffski, S Micheel and H Hecker. Annals of Oncology 13 October, 308-317, 2002.
  9. Bone Mineral Density in PreMenopausal Women Treated for Node - Positive Early Breast Cancer with 2 Years of Goserelin or 6 months of Cyclophosphamide, Methotrexate, and 5-Fluorouracil (CMF). I Fogelman, G M Blake, R Blamey, M Palmer, W Sauerbrei, M Schumacher, D Serin, A Stewart and W Wilpshaar. Osteoporosis Int (2003) 14: 1001-1006
  10. Costs incurred by patients in Advanced Colorectal Cancer Therapy: A Comparison of Raltitrexed (Tomudex) and 5-Fluorouracil Plus Leucovorin. Mark Sculpher, Mike Palmer and Anne Heyes. Pharmacoeconomics, 17: 361-370 April 2000
  11. Measuring Quality of Life : Impact of Chemotherapy for Advanced Colorectal Cancer: Experience from Two Recent Large Phase III Trials. H Anderson, M K Palmer. British Journal of Cancer (1998) 77 (Supplement 2), 9-14
  12. Haematological and Non-Haematological Toxicity after 5-Fluorouracil and Leucovorin in Patients with Advanced Colorectal Cancer is Significantly Associated with Gender, Increasing Age and Cycle Number. J Zalcberg, D Kerr, L Seymour and M Palmer. European J of Cancer, 34, 1871-, 1998.
  13. An Evaluation of the Effectiveness and Safety of Razoxane when used as an Adjunct to Surgery in Colo-Rectal Cancer. Report of a Controlled Randomised Study of 601 patients. R D Kingston, J W L Fielding, M K Palmer. Int. J. Colorect Dis (1993) 8:106-110
  14. Peri-operative Heparin: A Possible Adjuvant to Surgery in Colo-Rectal Cancer? R D Kingston, J W L Fielding, M K Palmer. Int. J. Colorect Dis (1993) 8:111-115
  15. The Relationship Between Histological Grade, Oestrogen Receptor Status, Events and Survival at 8 Years in the NATO (‘Nolvadex’) Trial. L Singh, A J Wilson, M Baum, W F Whimster, I H Birch, I M Jackson, C Lowery and M K Palmer. Br J Cancer, 1988, 57, 612-614.
  16. Controlled Trial of Tamoxifen as a Single Adjuvant Agent in the Management of Early Breast Cancer. Analysis at Eight Years by ‘Nolvadex’ Adjuvant Trial Organisation. Br J Cancer, 1988, 57, 608-611.
  17. Radiation Dose and Leukaemia Risk in Patients Treated for Cancer of the Cervix. John D Boice Jr, et al. Journal of National Cancer Institute, 79, 6 December 1987.
  18. Thirty-four Year Follow-up of Patients with Breast Cancer in a Clinical Trial of Post-operative Radiotherapy. M K Palmer and G G Ribeiro. Br Med J, 19th October 1985, 291, 1088-1091.
  19. Chemoimmunotherapy for metastatic malignant melanoma using vincristine, DTIC and BCG. Eur J Cancer, 1981, 17(4), 465-469.
  20. Cancer in Cumbria: the Windscale Connection. J Urquhart, M Palmer, J Cutler. Lancet, 1984, i, 217-218.
  21. Childhood leukaemia and social status. (Letter). I M Hann, M K Palmer, P H Morris-Jones, D I Evans. Lancet 1981, 3, 1282-3.
  22. Cervical lymph node biopsy - a study of its morbidity.Peter Gooder and Michael Palmer. Laryngology and Otology, 1984, 98, 1031-1040.
  23. The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin’s disease. A report from the Manchester Lymphoma Group. Clinical Radiology, 1985, 36, 449-454.
  24. Adjuvant low dose radiation in childhood T-cell leukaemia/lymphoma. (Report from the United Kingdom Children’s Cancer Study Group) M G Mott, J M Chessells, M L N Willoughby, J R Mann, P H Morris-Jones, J S Malpas and M K Palmer. Br. J. Cancer, 1984, 50, 457-462.
  25. Adjuvant low dose radiation in childhood non-Hodgkin’s lymphoma. (Report from the United Kingdom Children’s Cancer Study Group) M G Mott, O B Eden and M K Palmer. Br. J. Cancer, 1984, 50, 463-469.
  26. Prognostic significance of pre-treatment serum B2-microglobulin levels in multiple myeloma. J Howard Scarffe, Heather Anderson, Michael K Palmer and Derek Crowther. Eur J Cancer Clin Oncology, 1983, 19, 10, 1361-1364.
  27. Adjuvant Tamoxifen for Operable Carcinoma of the breast: report of a clinical trial by the Christie Hospital and Holt Radium Institute. Gerald Ribeiro and M K Palmer. Br Med J 1983, 286, 827,830.
  28. “Clinical Trial Methods” In “The Radiotherapy of Malignant Disease”. Springer-Verlag.
  29. Lymphocyte cytotoxicity in melanoma patients undergoing immunotherapy. N Thatcher, R Swindell, M K Palmer and D Crowther. Cancer Research Campaign.
  30. Une etude prospective randomisee sur 2 types de vagotomie dans l’ulcere duodenal chronique: surveillance de 4 annes. Par C G Koffman, D J Hay, P C Ganguli, J B Elder, I E Gillespie, S M Mantoudis, D E F Tweedle, P F Schofield, et M Palmer (Manchester). Medicine et Hygeine No 1455, 27, Janvier 1982.
  31. Prognostic Factors in Breast Cancer. M K Palmer, J P Lythgoe, A Smith. Br J Surgery, 69(12), 697-698, 1983.
  32. Manchester Regional Breast Study, 5 and 10 year Results. J P Lythgoe, M K Palmer. Br J Surgery, 69(12), 693-696, 1983.
  33. Randomised Clinical Trial of Levonantrodol and Chlorpromazine in the prevention of Radiotherapy induced vomiting. Helen H Lucraft, M K Palmer. Clinical Radiology, 1982, 33(6), 621-622.
  34. A Prospective Randomised Trial of Vagotomy in Chronic Duodenal Ulceration: 4 Year Follow-up. C G Koffman, D J Hay, P C Ganguli, J B Elder, I E Gillespie, S M Mantoudis, D E F Tweedle, P F Schofield, M Palmer. Br J Surgery.
  35. The Spatial Organisaion of the Hierarchical Proliferative Cells of the Crypts of the Small Intestine into Clusters of “Synchronised” cells. C S Potton, S Chwalinski, R Swindell, M K Palmer. Cell Tissue Kinet, 1982, 15, 351-370.
  36. Ewing’s Sarcoma: Results of Combined Treatment in a Population Based Series of Patients, 1958-1977. J F Babel, D Pearson and M K Palmer. Cancer (in press).
  37. Factors influencing Salvage Cystectomy Results. D Osborne, R Honan, M K Palmer, D McIntyre, R J Barnard, R S Pointon. British Journal of Urology, 1982, 54, 122-125.
  38. Haemoglobin and prognosis in childhood acute lymphoblastic leukaemia. Ian M Hann,  Howie Scarffe, Michael K Palmer, David I K Evans, and Patricia H Morris-Jones. Archives of Disease in Childhood, 1981, 56, 684-686.
  39. Malignant Melanoma in Children and Adolescents. Charles B Pratt, Michael K Palmer, Nicholas Thatcher, Derek Crowther. Cancer, 1981, 47(2), 393-397.
  40. Relationship Between Serum Alpha-Fetoprotein, Cirrhosis and Survival in Hepatocellular Carcinoma. P J Johnson, W M Melia, M K Palmer, B Portmann, R Williams. Br J Cancer, 1981, 44(4), 502-505.
  41. Low IgG or IgA: a further indicator of poor prognosis in Childhood ALL. I M Hann, P H Morris-Jones, D I K Evans, C M Addison, M K Palmer and J H Scarffe. Br J Cancer, 41, 317-319, 1980.
  42. The Prognostic Significance of Morphological Features in Childhood Acute Lymphoblastic Leukaemia. I M Hann, D I K Evans, M K Palmer, P H Morris-Jones and C Howarth. Clin Lab Haemat. 1979, 1, 215-226.
  43. Relationship Between the Pretreatment Proliferative Activity of Marrow Blast Cells and Prognosis of Acute Lymphoblastic Leukaemia of Childhood. J H Scarffe, I M Hann, D I K Evans, P Morris-Jones, M K Palmer, J S Lelleyman and D Crowther. Br J Cancer, 41, 764-771, 1980.
  44. A Score at Diagnosis for Predicting Length of Remission in Childhood Acute Lymphoblastic Leukaemia. M K Palmer, I M Hann, P M Jones and D I K Evans. Br J Cancer, 1980, 42, 841-849.
  45. Routine Bone Marrow in the Management of Acute Lymphatic Leukaemia: an assessment. C Howarth, A Heppleston, R Campbell, P Morris-Jones, D I K Evans and M K Palmer. J Clinical Path, 1981, 34, 483-485.
  46. Renal Size as a Prognostic Factor in Childhood Acute Lymphoblastic Leukaemia. I M Hann, P D Lees, M K Palmer, S Gupta and P H Morris-Jones. Cancer 48: 207-209, 1981.
  47. Intensive Combination Chemotherapy with Vincristine, Adriamycin and Prednisolone (VAP) in the Treatment of Diffuse Histology Non-Hodgkin’s Lymphoma. G Blackledge, H Bush, J Chang, D Crowther, D P Deakin, G Dodge, J V Garrett, M Palmer, D Pearson, J H Scarffe, I D H Todd and P M Wilkinson. European J Cancer, 16, 1459-1468, 1980.
  48. An Analysis of the Fate of Patients Treated Radically for Glottic Carcinoma of the Larynx. R D Hunter and M K Palmer. Clinical Radiology, 31, 499-452, 1980.
  49. Clinical Haematological and Radiological Features of Children Presenting with Lymphoblastic Mediastinal Masses. P M Mathew, D R Prangell, A J L Cole, F G Hill, K J Shah, P H Morris-Jones, J Martin, M K Palmer, E N Thompson, O B Eden, M G Mott and R J Mann. Medical and Pediatric Oncology 8: 193-2-4, 1980.
  50. Thirty Years Experience of Breast Cancer Trials in Manchester Statistical Aspects. M K Palmer. In “Clinical Trials in Early Breast Cancer”. Ed H R Scheurlen, G Weckesser and I Armbruster, Springer-Verlag, 1979.
  51. Survival Studies using a computer-based Hospital registry of 29,000 cancer patients. M K Palmer. In “Controversies in Cancer: Design of Trials and Treatment”. Ed Henri J Tagnon and Maurice J Staquet. Masson Publishing USA Inc 1979.
  52. The Prognostic Significance of Radiological and Symptomatic Bone Involvement in Childhood Acute Lymphoblastic Leukaemia. I M Hann, S Gupta, M K Palmer and P H Morris-Jones. Medical and Paediatric Oncology, 6: 51-55, 1979.
  53. Spinal Cord Compression in Myeloma. W J Benson, J H Scarffe, I D H Todd, M K Palmer, D Crowther. British Medical Journal, 1979, 1, 1541-1544.
  54. Career Preferences of Doctors Qualifying in the United Kingdom in 1977. J Parkhouse, M K Palmer and B A Hambleton. Health Trends, 1979, 11, 35-37.
  55. The Structure of the Human Thyroid in relation to Aging and Focal Thyroiditis. M Harris, M K Palmer. Journal of Pathology, 130, 99-104, 1980.
  56. A Prospective Randomised Trial of Vagotomy in Chronic Duodenal Ulceration. C G Koffman, J B Elder, I E Gillespie, P C Ganguli, D G Ostick, D J Cowley, I W Dymock, D E F Tweedle, P F Schofield, C D R Pengelly, M Shafiq, D R Shreeve and M K Palmer. British Journal of Surgery, 66, 1979, 145-148.
  57. Lymphocyte Cytoxicity in Melanoma Patients undergoing Immunotherapy. N Thatcher, R Swindell, M K Palmer and D Crowther. In “Immunodiagnosis and Immunotherapy of Malignant Tumours: Relevance to Surgery” Edited by H D Flad, C Herfarth and M Betzler. Springer-Verlag, 1979.
  58. Career Preferences of Doctors Qualifying in Britain in 1976. J Parkhouse, M K Palmer. Health Trends, 1979, 11, 4-6.
  59. Letter to the Lancet. Sex and Prognosis in Childhood Acute Lymphoblastic Leukaemia. D I K Evans, P H Morris-Jones, I M Hann, M K Palmer. Lancet, 2, 522-523, 1978.
  60. Testicular Histology after Combination Chemotherapy in Childhood for Acute Lymphoblastic Leukaemia. M Lendon, I M Hann, M K Palmer, S M Shalet, P H Morris-Jones. Lancet, 2, 439-440, 1978.
  61. “The Statistical Analysis of Survival following Treatment for Cancer”. M K Palmer. PhD Thesis, 1978, University of Manchester.
  62. Ewing’s Sarcoma, adjuvant chemotherapy and pathologic fracture. J G Rosenstock, P Morris-Jones, D Pearson and M K Palmer. European Journal of Cancer, 14, 7, 799-803, 1978.
  63. Bone Marrow Fibrosis in ALL of Childhood. I Hann, D I K Evans, H B Marsden, P Morris-Jones, M K Palmer. Journal of Clinical Pathology, 31, 313-315, 1978.
  64. Piracetam in Chronic Brain Failure. S Lloyd-Evans, J C Brocklehurst, M K Palmer. Current Medical Research and Opinion, 6, 5, 351-357, 1979.
  65. Fracture of the femur in old age: a two centre study of associated clinical factors and the cause of the fall. J C Brocklehurst, A N Exton-Smith, S M Lempert-Barber, L P Hunt and M K Palmer. Age and Aging, 7, 7-15, 1978.
  66. Observer variation in the examination of knee joints. J S Marks, M K Palmer, M Burke, P Smith. Annals of Rheumatic Diseases, 37, 376-377, 1978.
  67. Management of Congenital adrenal hyperplasia: urinary steroid estimations - review of their value. C Bailey, G M Komrower, M K Palmer. Archives of Diseases in Childhood, 53, 132-135, 1978.
  68. Lymphocyte Function related to Survival Curves in Patients with Metastatic Melanoma treated by Chemo-immunotherapy. N Thatcher, M K Palmer, R Swindell and D Crowther. Medical and Paediatric Oncology, 4, 1, 59-70, 1978.
  69. Assessment of Drug Therapy in Chronic Brain Failure. S Lloyd-Evans, J C Brocklehurst and M K Palmer. Gerontology, 24: 304-311, 1978.
  70. Histopathological Study of the First Medical Research Council Nephroblastoma Trial. W Lawler, H B Marsden, M K Palmer. Cancer, 40, 4, 1519-1525, 1977.
  71. Lympocyte Function and Response to Chemo-Immunotherapy in patients with Metastatic Melanoma. N Thatcher, M K Palmer, N Gasiunas, D Crowther. British Journal of Cancer, 1977, 36, 741-762.
  72. Breast Carcinoma associated with Pregnancy: A Clinician’s Dilemma. G G Ribeiro and M K Palmer. British Medical Journal, 1977, 2, 1524-1527.
  73. Bacteriuria in Geriatric Hospital Patients: its correlates and management. J C Brocklehurst, Peter Bee, Denis Jones and M K Palmer. Age and Ageing, 1977, 6, 240-245.
  74. A Comparative Study for White Blood Cell Counts below 2.0 x 109/L using Coulter Counter Model - S and Counting Chamber. K Hurd, M K Palmer, S Hull. Journal of Clinical Pathology 1977, 30, 1005-6.
  75. Barbiturates and Fractures (Letter to the Editor). J C Brocklehurst, A N Exton-Smith, S M Lempert-Barber, M K Palmer. British Medical Journal, 10 September 1977, 2, 699.
  76. Career Preferences of doctors qualifying in 1975.J Parkhouse, M K Palmer. British Medical Journal, 2 July 1977, 2, 25-27.
  77. Measuring Partial Thromboplastin time: An international collaborative study. L Poller, J M Thomson, M K Palmer. Lancet 2, 842-846, 1976.
  78. Prognostic Factors in Oral Cancer. E C Easson and M K Palmer. Clinical Oncology, 1976, 2, 191-202.
  79. E Rosette - forming cells in Mother and Newborn. D I K Evans, N Vyramuthu and M K Palmer. Lancet, 15 May 1976, Letter to the Editor.
  80. Distribution of Survival Times of 12,000 Head and Neck Cancer patients who died with their disease. R F Mould, T Hearnden, M K Palmer and G C White. British Journal of Cancer, 34, 180-190, 1976.
  81. The Management of Glottic Carcinoma by Primary Irradiation with Surgery in Reserve. J G Stewart, J R Brown, M K Palmer and A Cooper. The Laryngoscope, Vol LXXXV, No 9, pp 1477-1484, Sept 1975.
  82. “Statistical Evaluation”. M K Palmer, S Trew, E C Easson. In “Cancer of the Uterine Cervix” Edited by E C Easson. W B Saunders, 1973, London.
  83. Wilms Tumour - H istologic Variation and Prognosis. W Lawler, H B Marsden and M K Palmer. Cancer, Vol 36, 1122-1126, 1975.
  84. Histological Patterns of Neuroblastoma related to prognosis and staging.  M Hughes, H B Marsden and M K Palmer. Cancer, Vol 34, 1706-1711, 1974.
  85. Inra-arterial infusion of solcoseryl: a clinical trial of a method of treatment for pre-gangrene of the lower limb. D Charlesworth, P L Harris, M K Palmer. British Journal of Surgery, Vol 62, Number 5, May 1975.
Copyright © - Mike Palmer, 2007-2010. Privacy Policy. All Rights Reserved.
Website design and hosting by Uxello.